Skip to main content

Table 1 Basic characteristics of patients with endometrial cancer according to tertiles of plasma total omega-3 PUFAa

From: Plasma omega-3 polyunsaturated fatty acids and recurrence of endometrial cancer

Variable

Tertile1

Tertile2

Tertile3

Pg

Total omega-3 PUFA (wt%)

< 4.03

4.04–4.99

> 5.00

 

No. of patients

65

66

64

 

Age at diagnosis

56.0(49.0–64.0)

57.0(50.0–61.0)

54.0(51.0–58.0)

0.28

Body mass index (kg/m2)

24.2(21.6–27.0)

24.0(21.8–27.3)

23.6(21.3–26.7)

0.36

Age at menarche, years

15.0(14.0–16.0)

15.0(14.0–17.0)

15.0(14.0–16.0)

0.49

Menopausal status

   

0.80

 Premenopausal

22(33.85)

20(30.3)

23(35.94)

 

 Postmenopausal

43(66.15)

46(69.70)

41(64.06)

 

Age at menopause, years

51.0(49.0–53.0)

50.0(49.0–53.0)

50.0(48.0–52.0)

0.056

Gravidity

   

0.94

 0–2

28(43.08)

28(43.94)

28(43.75)

 

 ≥3

37(56.92)

37(56.06)

36(56.25)

 

Full-term birth

   

0.59

 0–2

45(69.23)

50(75.76)

47(73.44)

 

 ≥3

20(30.77)

16(24.24)

17(26.56)

 

Abortion (yes), %

37(56.92)

39(59.09)

39(60.94)

0.64

Hormonal therapy (ever), %

3(4.62)

3(4.55)

6(9.38)

0.48

Hypertension (ever), %

15(23.08)

16(24.24)

11(17.19)

0.42

History of other cancer (ever), %b

2(3.08)

3(4.55)

6(9.38)

0.12

Family history of cancer (ever), %c

17(26.15)

17(25.76)

11(17.19)

0.23

Long-term medication history (ever), %d

9(13.85)

15(22.73)

11(17.19)

0.66

FIGO stage

   

0.85

 I-II

53(81.54)

55(83.33)

53(82.81)

 

 III-IV

12(18.46)

11(16.67)

11(17.19)

 

Grade

   

0.86

 Low-grade (1–2)

54(83.08)

58(89.23)

53(84.13)

 

 High-grade (3)

11(16.92)

7(10.77)

10(15.87)

 

Myometrial invasion

   

0.92

 < 50%

49(75.38)

46(71.88)

48(76.19)

 

 ≥50%

16(24.62)

18(28.13)

15(23.81)

 

Histological type

   

0.69

 Endometrioid adenocarcinoma

62(95.38)

61(93.85)

60(93.75)

 

 Others

3(4.62)

4(6.15)

4(6.25)

 

Extrauterine Involvemente

   

0.95

 Negative

59(90.77)

58(90.63)

57(90.48)

 

 Positive

6(9.23)

6(9.38)

6(9.52)

 

Lymph node involvementf

   

0.78

 Negative

56(86.15)

55(83.33)

56(87.5)

 

 Positive

6(9.23)

5(7.58)

4(6.25)

 

 Unknown

3(4.62)

6(9.09)

4(6.25)

 

Adjuvant treatment

   

0.86

 None

41(63.08)

44(66.67)

39(60.94)

 

 Chemotherapy or radiotherapy

20(30.77)

20(30.30)

22(34.38)

 

 Unknown

4(6.15)

2(3.03)

3(4.69)

 
  1. aTotal plasma omega-3 PUFA was defined as the sum of ALA, EPA, DPA and DHA. Data are presented as proportions for categorical data, medians and interquartile ranges for continuous data
  2. bHistory of other cancer, including breast cancer, thyroid cancer, rectal cancer
  3. Long-term medication history, including anti-cancer drugs, blood pressure drugs, diabetes
  4. cFamily history of cancer: immediate relatives who have a history of any cancer were marked as yes, the cancer including Lung cancer, gastric cancer, colorectal cancer, endometrial cancer, liver, gallbladder, ovarian cancer, esophageal cancer
  5. dLong-term medication history, including anti-cancer drugs, blood pressure drugs, diabetes
  6. eExtrauterineInvolvement: any of the adnexa or vagina or parametrialwas involved
  7. fLymph node involvement: any of the Pelvic lymph node involvement or Para-aortic lymph node involvement was involved
  8. gP values were obtained using the Chi-Square test for categorical data and linear regression for continuous data
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us